3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
January 2026 in “Dermatology and Therapy” Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
7 citations
,
April 1992 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Women with non-classical congenital adrenal hyperplasia have higher levels of certain steroids, which can be reduced by treatment.
13 citations
,
December 2020 in “BMJ Open Diabetes Research & Care” Changes in SHBG levels don't predict diabetes risk reduction.
August 2010 in “Oncology Times” Provenge extends prostate cancer survival by about 4 months.
2 citations
,
October 2022 in “Dermatologic Therapy” Baricitinib may effectively treat lichen planopilaris.
The new gel for hair loss is safe, effective, and reduces side effects.
13 citations
,
October 2023 in “Pharmaceutics” The new nasal gel for schizophrenia improved drug absorption and brain effects in rats.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
April 2023 in “Journal of Pakistan Medical Association” Baricitinib is effective in promoting hair growth in severe alopecia areata.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
22 citations
,
September 2008 in “International Journal of Dermatology” The case suggests a possible autoimmune link between lichen sclerosus and vitiligo.
9 citations
,
May 2021 in “Frontiers in aging neuroscience” Taking triterpenoids from Ganoderma lucidum over a long time can help slow down brain aging and improve overall health in mice.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
12 citations
,
November 2017 in “European Annals of Allergy and Clinical Immunology” Omalizumab can cause temporary hair loss but still works well for chronic urticaria.
40 citations
,
March 1984 in “Acta dermato-venereologica” Etretinate has only moderate effects on localized scleroderma and lichen sclerosus.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
March 2026 in “Korean Journal of Clinical Pharmacy” In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.
January 2021 in “American journal of dermatological research and reviews” The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
16 citations
,
June 2015 in “Drug Design Development and Therapy” The new formulation improves dutasteride's absorption when taken orally.
39 citations
,
January 2008 in “World Journal of Gastroenterology” Pegylated interferon-alpha 2a can cause a rare nerve disorder, but early treatment can lead to full recovery.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
3 citations
,
January 2022 in “Journal of Cosmetic Dermatology” Bicalutamide, a drug with a good safety profile, is a promising new treatment for female pattern hair loss.